A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

October 24, 2011

Victrelis Keeps Hep C Viral Load Undetectable for 24 Weeks in 7 of 10 Coinfected Patients

Seventy percent of people coinfected with HIV and genotype 1 hepatitis C virus (HCV) have undetectable HCV viral loads after 24 weeks of treatment with Merck’s HCV protease inhibitor Victrelis (boceprevir) combined with pegylated interferon and ribavirin, according to interim study results reported at the annual meeting of the Infectious Disease Society of America (IDSA) on Saturday, October 22, in Boston.

Victrelis, like Vertex Pharmaceuticals’ Incivek, was approved in May 2011 for the treatment of chronic genotype 1 HCV—the most common, most difficult-to-treat form of the liver infection in the United States. Neither drug has been approved specifically for people coinfected with HIV and HCV, given a lack of safety and efficacy data from clinical trials involving patients living with both diseases. However, Phase II studies are ongoing, and Phase III clinical trials are planned.

Earlier this year, at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), experts got their first glimpse at the efficacy of the HCV protease inhibitors in people living with HIV/HCV coinfection. Twelve-week preliminary results from a Phase II study suggested that 68 percent of those treated with the Incivek plus pegylated interferon and ribavirin had undetectable HCV viral loads at week 12—known as an early virologic response (EVR), an excellent sign of hepatitis C being cured once treatment is stopped—compared with 14 percent of those receiving pegylated interferon/ribavirin alone. 

The preliminary Victrelis results, reported at IDSA by Mark Sulkowski, MD, of the Johns Hopkins University School of Medicine, comes from a clinical trial that randomized 100 coinfected individuals who hadn’t yet been treated for their HCV disease to receive either Victrelis or a placebo plus pegylated interferon and ribavirin. All patients were on stable antiretroviral therapy—unboosted protease inhibitors, non-nucleoside reverse transcriptase inhibitors, Videx (didanosine) and Retrovir (zidovudine) were not permitted because of possible drug interactions—and all patients had undetectable viral loads upon entering the study.

The analysis reported by Sulkowski involved a total of 98 study volunteers: 64 patients in the Victrelis group and 34 patients in the control group. All patients received a four-week lead-in with pegylated interferon plus ribavirin alone followed by the addition of Victrelis or placebo for 44 weeks.

At 12 weeks, 56.5 percent of patients in the Victrelis group, compared with 25 percent of those in the placebo group, had undetectable HCV viral loads, which translated into a 31.5 percent difference between the two groups.

At 24 weeks, 70.5 percent of those in the Victrelis group had undetectable viral loads, compared with 34.4 percent of those in the placebo group. This translated into a 36.1 percent difference between the two groups.

In the study of Incivek reported at CROI, also by Sulkowski, the difference between the placebo group and treatment group was 44 percent. However, the studies were different enough in their design and study population—for example, nearly one quarter of patients in the Incivek study were not on antiretroviral therapy during the study—to make comparisons between the two drugs difficult at best.

Preliminary safety data for Victrelis involving the coinfected patients were similar to those documented in patients infected only with HCV.

The most common side effects associated with taking Victrelis, compared with placebo, were low neutrophil counts (13 percent versus 3 percent), abnormal taste (25 versus 15 percent), vomiting (25 versus 15 percent), fevers (34 versus 21 percent), headache (28 versus 12 percent) and decreased appetite (30 versus 18 percent).

In conclusion, Sulkowski’s group reported, Victrelis plus pegylated interferon/ribavirin was associated with higher rates of undetectable HCV viral loads at weeks 12 and 24. While there were more side effects among those receiving Victrelis, compared with placebo, the overall safety and tolerability profile was similar to that observed in studies of patients only infected with HCV.

Follow-up data from the Phase II studies of Victrelis and Incivek are awaited—notably the rates of undetectable viral loads 24 weeks after the yearlong therapies are discontinued, which determine whether or not the infection has been cured.

Search: hepatitis C, victrelis, coinfection, HIV, interim, SVR, cure, protease inhibitors, direct acting antivirals, daa


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chipper52
    Palm Springs
    California


    koffeeboss
    Tucson
    Arizona


    Sexynyrican
    Brooklyn
    New York


    jacob2608
    Panama City Beach
    Florida
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.